-
Oct 8, 2024 | 
brnw.ch | Jeffrey Weber |Mark Middleton |Georgia Yates
ORIGINAL REPORTS IntroductionMelanoma accounts for 90% of all skin cancer-related deaths.1 The intention of adjuvant therapy in patients with melanoma is to prolong recurrence-free survival (RFS), that is, to reduce or eliminate the risk of recurrence or disease-related mortality and ultimately extend overall survival (OS).
-
Apr 25, 2024 | 
medscape.com | Jeffrey Weber
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts Manage Email Alerts
-
Apr 18, 2024 | 
medscape.com | Jeffrey Weber
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts Manage Email Alerts
-
Mar 25, 2024 | 
obroncology.com | Jeffrey Weber |Robert A. Figlin
The U.S. Food and Drug Administration’s recent accelerated approval for a tumor-infiltrating lymphocytes (TIL) therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work with the treatment in the late 1980s, discusses the breakthrough with Robert A.
-
Feb 8, 2024 | 
onclive.com | Jeffrey Weber
February 8, 2024Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma. Jeffrey S.
-
Nov 28, 2023 | 
onclive.com | Jeffrey Weber
Jeffrey S. Weber, MD, PhD, deputy director, codirector, the Melanoma Research Program, NYU Langone Perlmutter Cancer Center, Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine, discusses the use of circulating-tumor DNA (ctDNA) dynamics when guiding treatment decision-making in melanoma, according to data from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881).
-
Nov 1, 2023 | 
onclive.com | Jeffrey Weber
Jeffrey S. Weber, MD, PhD, deputy director, codirector, the Melanoma Research Program, NYU Langone Perlmutter Cancer Center, Laura and Isaac Perlmutter Professor of Oncology, NYU Grossman School of Medicine, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial (NCT03897881) of mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) in resected high-risk melanoma.
-
Oct 24, 2023 | 
medscape.com | Jeffrey Weber
This transcript has been edited for clarity. This is Dr Jeffrey Weber. I'm a medical oncologist at the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health in New York City. Today, I'd like to report to you about three abstracts presented at this year's American Society of Clinical Oncology (ASCO) meeting in Chicago, which I think have significance and importance as they relate to melanoma practice and care.
-
Mar 3, 2023 | 
medscape.com | Jeffrey Weber
This transcript has been edited for clarity. I'm Dr Jeffrey Weber, medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health in New York City. Today, we'll be discussing some very important abstracts presented at the recent Society for Melanoma Research meeting in Edinburgh, Scotland.
-
Mar 1, 2023 | 
medscape.com | Jeffrey Weber
This transcript has been edited for clarity. I'm Dr Jeffrey Weber, a medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health in New York City. Today, I'm reporting to you not on a presentation at a meeting or on a published communication, but on a press release, which I think has very important implications for the field of oncology. It's a press release that came out recently from both Moderna and Merck, who have collaborated on a clinical vaccine trial.
